Malaysia is aiming to produce its first locally made human vaccine by 2028 as part of a broader push to reduce dependence on imported supplies. The plan was outlined in Kuala Lumpur by Science, Technology and Innovation Minister Chang Lih Kang.
According to the minister, Malaysia’s first domestically produced human vaccine will be intended for illnesses such as pneumonia, meningitis, sepsis and blood infections. The initial product was described as a 13-valent vaccine, signaling a targeted approach to preventing serious infectious diseases.
The move highlights Malaysia’s interest in strengthening its own vaccine manufacturing capacity rather than relying heavily on overseas producers. Building local production could help improve supply security and support the country’s longer-term public health planning.
While full details on development timelines and production scale were not outlined in the available report, the 2028 target marks a significant milestone for Malaysia’s medical and biotechnology ambitions. If achieved, it would represent the country’s first step into local human vaccine production.
